Using a newly generated monoclonal antibody （2E6） against human B7-H3, we explored the expression of the molecule on dendritic cells derived from monocytes （Mo-DCs）. Its expression was examined by means of immunos...Using a newly generated monoclonal antibody （2E6） against human B7-H3, we explored the expression of the molecule on dendritic cells derived from monocytes （Mo-DCs）. Its expression was examined by means of immunostaining and flow cytometric （FCM） analysis. The results showed that B7-H3 was expressed in the course of Mo-DC maturation induced with interleukin 4 （IL-4） and granulocyte/macrophage colony-stimulating factor （GM-CSF）. The expression could be detected at all the stages of Mo-DC differentiation, and remained at a quite stable level. Interestingly, B7-H3 was not expressed by T cells and B cells, even these cells were activated respectively by PHA or PWM. A weak expression could be detected on resting monocytes. These data showed that constitutive expression of B7-H3 at a high level was found on imDCs and mDCs derived from monocytes. Due to no expression on T cells and B cells, we speculate that B7-H3 might be another valuable molecule marker for Mo-DCs.展开更多
B7-H1, a recently described member of the B7 family of costimulatory molecules, is thought to be involved in tumor immune escape by inducing T-cell apoptosis. In order to investigate the relationship between B7-H1 and...B7-H1, a recently described member of the B7 family of costimulatory molecules, is thought to be involved in tumor immune escape by inducing T-cell apoptosis. In order to investigate the relationship between B7-H1 and immune escape of bladder cancer, B7-H1 expression in 50 cases of bladder cancer was detected by using immunohistochemical method. Survival curves were con- structed using the Kaplan-Meier method and independent prognostic factors were evaluated using the Cox regression model. Our results showed that the positive rate of B7-H1 immunostaining in normal bladder tissue and bladder cancer was 0 and 72% respectively. The expression of B7-H1 was strongly associated with the pathological grade, clinical stage and recurrence （P〈0.05）. The survival rate was significantly lower in patients with B7-H1 positive group than in those with B7-H1 negative group and multi-variable analysis revealed that B7-H1 could be regarded as an independent factor in evaluating the prognosis of bladder cancer. It is concluded that the expression of B7-H1 is strongly associated with neoplastic progression and prognosis of bladder cancer. The manipulation of B7-H1 may become a beneficial target for immunotherapy in human bladder cancer.展开更多
本研究旨在探讨PD-L1和PD-L2在卵巢癌组织中的表达及其与疾病预后的关系。采用免疫组化法检测77例卵巢癌组织PD-L1和PD-L2的表达,取10例卵巢子宫内膜异位囊肿组织作为对照;Kaplan-Meier法比较不同PD-L1、PD-L2表达水平单独或联合分析对...本研究旨在探讨PD-L1和PD-L2在卵巢癌组织中的表达及其与疾病预后的关系。采用免疫组化法检测77例卵巢癌组织PD-L1和PD-L2的表达,取10例卵巢子宫内膜异位囊肿组织作为对照;Kaplan-Meier法比较不同PD-L1、PD-L2表达水平单独或联合分析对患者术后总生存期(overall survival,OS)的影响;流式细胞术分离TIL及其亚群分析PD-L1、PD-L2的表达。结果显示,PD-L1和PD-L2主要表达在卵巢癌细胞膜上和细胞质中。PD-L1在卵巢癌组织中的高表达率为44.16%,PD-L2的高表达率为22.08%,对照组均低表达。PD-L1表达与患者国际妇产科联盟(International Federation of Gynecology and Obstetrics,FIGO)分期有统计学意义(P=0.026)。Kaplan-Meier法生存分析显示,PD-L1、PD-L2高表达组OS较低表达组显著缩短[风险比(hazard ratio,HR)=2.689,P=0.0005;HR=2.204,P=0.0105]。多因素Cox比例风险模型显示,PD-L1高表达(HR=2.275,P=0.023)、PD-L2高表达(HR=2.314,P=0.021)、FIGO分期(HR=11.229,P=0.024)是影响卵巢癌患者生存的独立危险预后因素。将PD-L1及PD-L2均低表达作为判断指标,OS显著延长(HR=3.396,P<0.0001)。结合前期研究结果,PD-L1阴性且T盒子转录因子(T-box transcription factor,T-bet)^+TIL高浸润的患者OS较其他患者更长(P=0.001),而PD-L1阳性且T-bet^+TIL低浸润的患者OS最短。研究提示PD-L1及PD-L2可能参与了卵巢癌的发生和发展,对卵巢癌的临床诊断及患者预后判断具有潜在价值。展开更多
基金supported by a grant from the National Natural Science Foundation of China(N0.30330540).
文摘Using a newly generated monoclonal antibody （2E6） against human B7-H3, we explored the expression of the molecule on dendritic cells derived from monocytes （Mo-DCs）. Its expression was examined by means of immunostaining and flow cytometric （FCM） analysis. The results showed that B7-H3 was expressed in the course of Mo-DC maturation induced with interleukin 4 （IL-4） and granulocyte/macrophage colony-stimulating factor （GM-CSF）. The expression could be detected at all the stages of Mo-DC differentiation, and remained at a quite stable level. Interestingly, B7-H3 was not expressed by T cells and B cells, even these cells were activated respectively by PHA or PWM. A weak expression could be detected on resting monocytes. These data showed that constitutive expression of B7-H3 at a high level was found on imDCs and mDCs derived from monocytes. Due to no expression on T cells and B cells, we speculate that B7-H3 might be another valuable molecule marker for Mo-DCs.
基金supported by a grant from Hubei Provin-cial Science and Technology Key Program Foundation of China (No. 2007AA402C60).
文摘B7-H1, a recently described member of the B7 family of costimulatory molecules, is thought to be involved in tumor immune escape by inducing T-cell apoptosis. In order to investigate the relationship between B7-H1 and immune escape of bladder cancer, B7-H1 expression in 50 cases of bladder cancer was detected by using immunohistochemical method. Survival curves were con- structed using the Kaplan-Meier method and independent prognostic factors were evaluated using the Cox regression model. Our results showed that the positive rate of B7-H1 immunostaining in normal bladder tissue and bladder cancer was 0 and 72% respectively. The expression of B7-H1 was strongly associated with the pathological grade, clinical stage and recurrence （P〈0.05）. The survival rate was significantly lower in patients with B7-H1 positive group than in those with B7-H1 negative group and multi-variable analysis revealed that B7-H1 could be regarded as an independent factor in evaluating the prognosis of bladder cancer. It is concluded that the expression of B7-H1 is strongly associated with neoplastic progression and prognosis of bladder cancer. The manipulation of B7-H1 may become a beneficial target for immunotherapy in human bladder cancer.
文摘本研究旨在探讨PD-L1和PD-L2在卵巢癌组织中的表达及其与疾病预后的关系。采用免疫组化法检测77例卵巢癌组织PD-L1和PD-L2的表达,取10例卵巢子宫内膜异位囊肿组织作为对照;Kaplan-Meier法比较不同PD-L1、PD-L2表达水平单独或联合分析对患者术后总生存期(overall survival,OS)的影响;流式细胞术分离TIL及其亚群分析PD-L1、PD-L2的表达。结果显示,PD-L1和PD-L2主要表达在卵巢癌细胞膜上和细胞质中。PD-L1在卵巢癌组织中的高表达率为44.16%,PD-L2的高表达率为22.08%,对照组均低表达。PD-L1表达与患者国际妇产科联盟(International Federation of Gynecology and Obstetrics,FIGO)分期有统计学意义(P=0.026)。Kaplan-Meier法生存分析显示,PD-L1、PD-L2高表达组OS较低表达组显著缩短[风险比(hazard ratio,HR)=2.689,P=0.0005;HR=2.204,P=0.0105]。多因素Cox比例风险模型显示,PD-L1高表达(HR=2.275,P=0.023)、PD-L2高表达(HR=2.314,P=0.021)、FIGO分期(HR=11.229,P=0.024)是影响卵巢癌患者生存的独立危险预后因素。将PD-L1及PD-L2均低表达作为判断指标,OS显著延长(HR=3.396,P<0.0001)。结合前期研究结果,PD-L1阴性且T盒子转录因子(T-box transcription factor,T-bet)^+TIL高浸润的患者OS较其他患者更长(P=0.001),而PD-L1阳性且T-bet^+TIL低浸润的患者OS最短。研究提示PD-L1及PD-L2可能参与了卵巢癌的发生和发展,对卵巢癌的临床诊断及患者预后判断具有潜在价值。
